Informed Investing
Subscribe
NewsArticlesLearnPodcastSubscribe

#AbbVie

NewsArticlesLearnPodcast
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside | The Motley Fool
SEPTEMBER 15, 2026

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside | The Motley Fool

Ken Griffin's Citadel has significantly increased its investment in AbbVie by over 500%, signaling a strategic shift towards defensive stocks amid market volatility. With a robust 2.6% dividend yield and a strong business foundation, including new drug developments and a solid aesthetics segment, AbbVie presents a compelling...

Read More >
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years
JULY 9, 2026

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

The healthcare sector remains a top choice for dividend stocks, with AbbVie (ABBV) emerging as a standout for income-seeking investors. AbbVie boasts a forward dividend yield of 2.65%, supported by robust revenue growth from its diverse drug portfolio, including Skyrizi and Rinvoq. Recent acquisitions, like Apogee Therapeutics,...

Read More >
Informed Investing
About UsContact
PrivacyTermsCopyright

Informed Investing is for informational and educational purposes only and is not financial, investment, tax, or legal advice. Nothing on this site constitutes a recommendation, solicitation, or offer to buy or sell any security or financial product. Investing involves risk, including loss of principal. Content may be developed with the assistance of analytical and automated tools, including AI systems, and is subject to human editorial review. Information may be incomplete, inaccurate, or outdated. You should independently verify information before acting on it and consult a qualified professional as appropriate.

© 2026 Informed Investing. All rights reserved.